Medplus Health Services has announced that one of its subsidiaries is experiencing a drug license suspension in the state of Andhra Pradesh. The healthcare retail chain has disclosed this regulatory development along with its assessment of the potential financial implications.

Financial Impact Assessment

The company has projected the revenue loss from this license suspension at ₹2.10 lakhs. This represents the estimated financial impact on the subsidiary's operations due to the regulatory action.

Regulatory Compliance Matter

The drug license suspension affects the subsidiary's ability to operate in Andhra Pradesh, a key market for pharmaceutical retail operations. Such regulatory actions typically require companies to address compliance issues before normal operations can resume.

The relatively modest projected revenue loss suggests that the affected subsidiary may represent a smaller portion of the company's overall operations in the region, or that the suspension may be expected to be resolved within a limited timeframe.

MedPlus Health Services Limited has informed stock exchanges about a regulatory action affecting its subsidiary operations. The company disclosed that Optival Health Solutions Private Limited, a subsidiary, received a drug license suspension order from the Assistant Director of Drugs Control Administration in Rangareddy, Telangana.

Regulatory Action Details

The suspension order specifically targets one store situated at Vanasthalipuram Ganesh Temple in Telangana. The regulatory action was taken under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.

Financial Impact

The company has quantified the potential financial impact of this regulatory action. MedPlus Health Services estimates a potential revenue loss of approximately ₹1.19 lakhs due to the one-day suspension of the drug license.

Regulatory Compliance

The disclosure was made pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, read with SEBI Circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024. The company has fulfilled its obligation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Company Communication

The information has been made available on the company's website at www.medplusindia.com and will also be accessible on the websites of BSE Limited and National Stock Exchange of India Limited. The disclosure was signed by Manoj Kumar Srivastava, Company Secretary & Compliance Officer, on December 31, 2025.